hepatitis B

Roche ties up again with Ascletis — this time on a commercial partnership for hep B drug
Endpoints
Wed, 11/21/18 - 12:20 pm
Roche
hepatitis B
China
Hong Kong
Ascletis
Pegasys
FDA guides development of finite therapies to cure HBV
BioCentury
Sun, 11/4/18 - 02:29 pm
FDA
hepatitis B
Arrowhead Pharmaceuticals Closes Agreements with Janssen Worth Up To $3.7 Billion
CP Wire
Wed, 10/31/18 - 11:03 am
Arrowhead Pharmaceuticals
Janssen
JNJ
hepatitis B
Johnson & Johnson pays $175M, commits to $1.6B in milestones for Arrowhead hepatitis B drug
Fierce Biotech
Thu, 10/4/18 - 10:22 am
JNJ
Arrowhead
hepatitis B
RNAi
Skirting a group of pioneers, Gilead partners with gene-editing upstart Precision Bio in hunt to cure hep B
Endpoints
Wed, 09/12/18 - 11:22 am
Gilead Sciences
hepatitis B
gene editing
Precision Biosciences
Arrowhead Shares Pop on Early Clinical Data for Hepatitis B Drug
Xconomy
Thu, 09/6/18 - 07:36 pm
Arrowhead Pharmaceuticals
hepatitis B
clinical trials
ARO-HBV
Gilead, Hookipa pen hepatitis B, HIV research collaboration
Fierce Biotech
Wed, 06/6/18 - 09:34 am
Gilead Sciences
Hookipa
hepatitis B
HIV
vaccines
drug development
Teva rolls out exclusive generic of Gilead's Viread at the end of an awful week
Fierce Pharma
Fri, 12/15/17 - 11:40 pm
Teva Pharmaceutical
Gilead Sciences
Viread
hepatitis B
HIV
antivirals
Dynavax's hepatitis B vaccine gets FDA nod on third try, shares up
Reuters
Sat, 11/11/17 - 11:09 am
Dynavax
hepatitis B
vaccines
FDA
HEPLISAV-B
Tiny hep B drug combo study touts potential of a ‘functional cure’ at little-known Replicor
Endpoints
Tue, 10/24/17 - 05:34 pm
hepatitis B
Replicor
REP 2139
With an FDA decision looming, Dynavax is shopping a deal on Heplisav — report
Endpoints
Mon, 10/2/17 - 11:14 am
FDA
Dynavax Technologies
Heplisav
vaccines
hepatitis B
J&J moves away from hep C due to rival drugmakers' cures
BioPharma Dive
Mon, 09/11/17 - 10:28 pm
JNJ
hepatitis C
JNJ-4178
R&D
hepatitis B
Dynavax shares dip after FDA asks for more time to sort out Heplisav post-marketing plan
Endpoints
Fri, 08/4/17 - 11:38 am
Dynavax
FDA
Heplisav
vaccines
hepatitis B
Data supports safety of Dynavax hepatitis B vaccine -U.S. FDA panel
Yahoo/Reuters
Sat, 07/29/17 - 09:43 am
Dynavax
vaccines
hepatitis B
Heplisav
FDA
advisory panels
J&J inks $879M vaccine deal with Bavarian Nordic
BioPharma Dive
Fri, 07/28/17 - 11:29 am
JNJ
vaccines
Bavarian Nordic
Janssen
hepatitis B
Dynavax shares slide as FDA review spotlights a hazy safety issue for Heplisav
Endpoints
Wed, 07/26/17 - 10:30 pm
Dynavax
FDA
Heplisav
hepatitis B
vaccines
VBI Vaccines takes a shot at HBV Phase 3
BioPharma Dive
Thu, 07/13/17 - 09:26 pm
VBI Vaccines
vaccines
Sci-B-Vac
hepatitis B
Gilead’s Vemlidy Hep B Drug Approved In EU
Investopedia
Sun, 01/15/17 - 11:16 am
Gilead Sciences
hepatitis B
Vemlidy
Europe
Gilead's Looming Challenge: A Plan B For HBV
Seeking Alpha
Tue, 11/22/16 - 11:35 am
Gilead Sciences
hepatitis B
GS-9620
Dynavax's stock plunges after disappointing FDA response to Hep-B treatment
Marketwatch
Mon, 11/14/16 - 11:41 am
Dynavax
hepatitis B
FDA
HEPLISAV-B

Pages